0001562180-19-003434.txt : 20190610
0001562180-19-003434.hdr.sgml : 20190610
20190610160405
ACCESSION NUMBER: 0001562180-19-003434
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190606
FILED AS OF DATE: 20190610
DATE AS OF CHANGE: 20190610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Enyedy Mark J
CENTRAL INDEX KEY: 0001586965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 19888616
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2019-06-06
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001586965
Enyedy Mark J
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.
CAMBRIDGE
MA
02142
true
false
false
false
Common Stock
2019-06-06
4
A
false
13700.00
0.00
A
17443.00
D
Stock Option (Right to buy)
4.23
2019-06-06
4
A
false
20100.00
0.00
A
2020-06-06
2029-06-06
Common Stock
20100.00
20100.00
D
The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
/s/ Nicole R. Hadas, attorney-in-fact for Mark J. Enyedy
2019-06-10